We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Ondine Biomedical Inc (OBI) NPV

Sell:8.00p Buy:9.00p 0 Change: No change
Market closed |  Prices as at close on 30 January 2026 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.00p
Buy:9.00p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 30 January 2026 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.00p
Buy:9.00p
Change: No change
Market closed |  Prices as at close on 30 January 2026 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Ondine expands use of Steriwave in Spain

    22 January 2026 14:53

    (Sharecast News) - Ondine Biomedical said on Thursday that it had expanded the use of its Steriwave nasal photodisinfection technology into ear, nose and throat surgery in Spain, following deployment across...

  • Ondine to present Steriwave analysis at Geneva conference

    3 September 2025 12:52

    (Sharecast News) - Ondine Biomedical said in an update on Wednesday that its health economic analysis of Steriwave nasal photodisinfection would be presented at the 12th International Conference on...

  • Ondine to pilot Steriwave at Mexico City hospital

    13 August 2025 14:50

    (Sharecast News) - Ondine Biomedical announced Wednesday that it will pilot its Steriwave nasal photodisinfection system at ABC Medical Center in Mexico City from September, marking the technology's...

  • Ondine completes landmark Steriwave study

    21 July 2025 12:30

    (Sharecast News) - Ondine Biomedical announced the completion of a landmark 291-patient clinical study using its Steriwave nasal photodisinfection technology in the intensive care unit at Royal Columbian...

  • Ondine Biomedical upbeat on new Steriwave test data

    9 June 2025 15:59

    (Sharecast News) - Ondine Biomedical announced new data from University College London on Monday, showing that its Steriwave photodisinfection technology is effective against Mucor, a highly lethal fungal...

  • Ondine's Steriwave adopted by Ottawa Heart Institute

    5 June 2025 12:28

    (Sharecast News) - Ondine Biomedical announced on Thursday that the University of Ottawa Heart Institute (OHI) had adopted its Steriwave nasal photodisinfection therapy as a standard of care for all cardiac...

  • Ondine appoints Alan Thomas as interim finance chief

    9 May 2025 12:50

    (Sharecast News) - Ondine Biomedical announced the appointment of Alan Thomas as its interim chief financial officer on Friday, with immediate effect, following the departure of Michael Behlke, who was...

  • Ondine Biomedical upbeat on cost-saving potential of Steriwave product

    9 April 2025 13:28

    (Sharecast News) - Ondine Biomedical said in an update on Wednesday that a new health economic analysis by the York Health Economics Consortium (YHEC) supported significant cost-saving potential from its...

  • Ondine appoints new finance, operations chief

    26 February 2025 12:39

    (Sharecast News) - Ondine Biomedical announced the appointment of Michael Behlke as its chief financial and chief operating officer on Wednesday, strengthening its leadership team as the company advanced its...

  • Ondine Biomedical gets $4m investment from HCA Healthcare subsidiary

    27 January 2025 15:44

    (Sharecast News) - Ondine Biomedical announced a $4m equity investment from hInsight-NX, a subsidiary of US medical facilities giant HCA Healthcare, on Monday, extending its cash runway through to the fourth...

  • Ondine enrols first patient in phase three clinical trial

    30 December 2024 10:02

    (Sharecast News) - Ondine Biomedical announced the launch of its phase three clinical trial for 'light-activated antimicrobial therapy to prevent surgical site infections' (LANTERN) on Monday,...

  • Ondine enrols first patient in phase three clinical trial

    30 December 2024 10:02

    (Sharecast News) - Ondine Biomedical announced the launch of its phase three clinical trial for 'light-activated antimicrobial therapy to prevent surgical site infections' (LANTERN) on Monday,...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2026. All rights reserved.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.